Evonetix, a next generation synthetic biology company leveraging semiconductor technology to generate long, double-stranded DNA with high-fidelity at scale, has added Colin McCracken as CEO. To date, the UK-based platform company has raised $45M led by Foresite, DCVC, Draper Esprit and Morningside.

McCracken brings over twenty years’ experience in commercial and business development roles. Prior to joining Evonetix he was SVP & Chief Commercial Officer at Fluidigm where he was responsible for leading all commercial activities, driving revenue growth, and expanding the Company’s global reach. He has delivered commercial success in numerous leadership positions, including Vice President & General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President & Head of European Sales at Life Technologies and National Sales Manager at Qiagen. See Full Press Release HERE